Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.

Cytokinetics stock has delivered strong multi year returns, yet its latest valuation checks point to a more mixed picture rather than a clear bargain or an obvious overvaluation. Cytokinetics has returned about 139% over the past 5 years, which puts extra focus on whether current holders are still being fairly compensated for the risks they are taking. The recent UK approval and reimbursement support for MYQORZO may support investor expectations for future revenue, while ongoing regulatory...

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.

Moby summary of Cytokinetics, Incorporated's Q2 2026 earnings call

Strong US commercial uptake and positive Phase 3 data position Cytokinetics for expanded market leadership in HCM treatment.

Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten in non-obstructive hypertrophic cardiomyopathy, or nHCM. Chief Executive Officer Robert Blum said t

Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.